Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14959156 | 0.77 | AKT1 (0.39) | PARP1HTR1ACTNNB1WNT3ANOTUM | |
| SCHEMBL4344995 | 0.77 | PARP1 (0.46) | PARP1HTR1ACTNNB1WNT3ANOTUM | |
| SCHEMBL15635817 | 0.74 | PARP1 (0.33) | PARP1HTR1ACTNNB1WNT3ANOTUM | |
| SCHEMBL30748852 | 0.74 | PARP1 (0.33) | PARP1HTR1ACTNNB1WNT3ANOTUM | |
| SCHEMBL11926946 | 0.74 | NOTUM (0.35) | PARP1HTR1ACTNNB1WNT3ANOTUM | |
| SCHEMBL16655910 | 0.72 | PIK3CD (0.33) | — | |
| SCHEMBL13861855 | 0.70 | BRD4 (0.31) | PARP1CTNNB1WNT3ANOTUM | |
| SCHEMBL14268235 | 0.70 | PARP1 (0.31) | PARP1NOTUM | |
| SCHEMBL14639682 | 0.70 | PARP1 (0.31) | PARP1NOTUM | |
| SCHEMBL470297 | 0.69 | CTNNB1 (0.46) | CTNNB1WNT3ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | PARP1 584/4885HTR1A 2965/4885CTNNB1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.